Product Code: GMDHC10634IDB
Summary:
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2018, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.
Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.
Report Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 2, 6, 6, 1, 12, 2 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Erectile Dysfunction - Overview
- Erectile Dysfunction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Erectile Dysfunction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Erectile Dysfunction - Companies Involved in Therapeutics Development
- Apricus Biosciences Inc
- Aquestive Therapeutics Inc
- Astellas Pharma Inc
- Biolab Farmaceutica Ltda
- Biopharm GmbH
- Biozeus Pharmaceutical SA
- Can-Fite BioPharma Ltd
- Fabre-Kramer Pharmaceuticals Inc
- Futura Medical Plc
- Humanetics Corp
- IntelGenx Corp
- Ion Channel Innovations LLC
- Karessa Pharma Holding AB
- Mezzion Pharma Co Ltd
- Mitsubishi Tanabe Pharma Corp
- N4 Pharma Plc
- NAL Pharmaceuticals Ltd
- Pharmicell Co Ltd
- SK Chemicals Co Ltd
- Suda Pharmaceuticals Ltd
- XuanZhu Pharma Co Ltd
- Yangtze River Pharmaceutical Group
- Erectile Dysfunction - Drug Profiles
- (finasteride + tadalafil) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- alprostadil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AP-185 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- avanafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BIO-300 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BL-214 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BZ-371 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Cellgram-ED - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CF-602 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- FKK-01PD - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- IPED-2015 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- libiguins - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MED-2002 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MED-2005 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- mirabegron ER - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pVAX-hSlo - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sildenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sildenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sildenafil citrate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SUD-003 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- T-6932 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TF-0092 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TPN-729 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TR-399 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- udenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vardenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- XZP-5849 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Yonkenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Erectile Dysfunction - Dormant Projects
- Erectile Dysfunction - Discontinued Products
- Erectile Dysfunction - Product Development Milestones
- Featured News & Press Releases
- Jun 26, 2018: Initiator Pharma announces MHRA approval for clinical trial
- Jun 19, 2018: iX Biopharma Obtains Approval and Registration of Wafesil for the Treatment of Male Erectile Dysfunction in Australia
- Jun 04, 2018: Initiator Pharma selects Clinical Site
- May 02, 2018: Best in Class Erectile Dysfunction Drug - DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99
- Jan 22, 2018: Initiator Pharma successfully completes the preclinical development of its Erectile Dysfunction drug candidate IPED2015 ahead of time
- Jan 04, 2018: Potential Breakthrough Treatment for Erectile Dysfunction
- Dec 15, 2017: Initiator Pharma reports positive results from the 28 days toxicology study in mini-pigs for its lead drug candidate IPED2015
- Nov 22, 2017: Initiator Pharma receives positive result from the toxicology and toxicokinetic studies for its lead drug candidate IPED2015
- Oct 31, 2017: Humanetics Presents Data on Potential Treatment to Prevent Erectile Dysfunction in Prostate Cancer Patients
- Oct 26, 2017: Initiator Pharma initiates toxicology and toxicokinetic studies for its lead drug candidate IPED2015
- Oct 10, 2017: N4 Pharma: Sildenafil PCT Update
- Sep 07, 2017: A busy summer is providing valuable and Positive Results from the first Maximum tolerated dose toxicology for drug Candidate IPED2015
- Aug 23, 2017: iX Biopharma Provides Update on PheoniX
- Jul 27, 2017: N4 Pharma: Filing of Patents and Sildenafil Update
- Jul 27, 2017: N4 Pharma: Update on Sildenafil clinical plans
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
